At a glance
ClinicalIndex Comparison RecordN/ACompleted· 14 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Retrospective Review of Valganciclovir Efficacy in Preventing CMV Disease in D+/R- Liver Transplant Recipients - A Non-Interventional Program
In Brief
An observational study for Cytomegalovirus Infections. Completed, enrolled 14 participants across 3 sites.
Detailed Summary
This retrospective review will evaluate the efficacy of Valcyte (valganciclovir) in preventing Cytomegalovirus (CMV) disease in D+/R- liver transplant recipients. Data from eligible patients will be collected for the 6 months following transplantation.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCytomegalovirus Infections
CountriesSwitzerland
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2010
Primary CompletionSep 2011
First PostedFeb 2014
TodayJul 2026
First PostedFeb 13, 2014
Enrollment StartJul 31, 2010
Primary CompletionSep 30, 2011
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 12.4 years ago